Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 299

1.

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.

Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ.

J Immunother Cancer. 2018 Oct 22;6(1):109. doi: 10.1186/s40425-018-0420-0.

2.

Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies.

Kroeger N, Li H, De Velasco G, Donskov F, Sim HW, Stühler V, Wells JC, Stukalin I, Heide J, Bedke J, Agarwal N, Parekh H, Rini BI, Knox JJ, Pantuck A, Choueiri TK, Chin Heng DY.

Clin Genitourin Cancer. 2018 Sep 12. pii: S1558-7673(18)30506-8. doi: 10.1016/j.clgc.2018.09.006. [Epub ahead of print]

PMID:
30341028
3.

Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.

Zahoor H, Barata PC, Jia X, Martin A, Allman KD, Wood LS, Gilligan TD, Grivas P, Ornstein MC, Garcia JA, Rini BI.

J Immunother Cancer. 2018 Oct 17;6(1):107. doi: 10.1186/s40425-018-0425-8.

4.

Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target.

Koshkin VS, Garcia JA, Reynolds J, Elson P, Magi-Galluzzi C, McKenney JK, Isse K, Bishop E, Saunders LR, Balyimez A, Rashid S, Hu M, Stephenson AJ, Fergany AF, Lee BH, Haber GP, Dowlati A, Gilligan T, Ornstein MC, Rini BI, Abazeed ME, Mian OY, Grivas P.

Clin Cancer Res. 2018 Oct 16. doi: 10.1158/1078-0432.CCR-18-1278. [Epub ahead of print]

PMID:
30327311
5.

Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Yip SM, Wells C, Moreira R, Wong A, Srinivas S, Beuselinck B, Porta C, Sim HW, Ernst DS, Rini BI, Yuasa T, Basappa NS, Kanesvaran R, Wood LA, Canil C, Kapoor A, Fu SYF, Choueiri TK, Heng DYC.

Cancer. 2018 Sep 15;124(18):3677-3683. doi: 10.1002/cncr.31595. Epub 2018 Oct 11.

PMID:
30307610
6.

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Oct 5. doi: 10.1038/s41591-018-0235-z. [Epub ahead of print]

PMID:
30291359
7.

Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.

Tzeng A, Diaz-Montero CM, Rayman PA, Kim JS, Pavicic PG Jr, Finke JH, Barata PC, Lamenza M, Devonshire S, Schach K, Emamekhoo H, Ernstoff MS, Hoimes CJ, Rini BI, Garcia JA, Gilligan TD, Ornstein MC, Grivas P.

Target Oncol. 2018 Oct;13(5):599-609. doi: 10.1007/s11523-018-0595-9.

PMID:
30267200
8.

Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery.

Almassi N, Gao T, Lee B, Stein RJ, Haber GP, Ornstein MC, Rini BI, Gilligan TD, Garcia JA, Stephenson AJ, Grivas P.

Clin Genitourin Cancer. 2018 Aug 22. pii: S1558-7673(18)30376-8. doi: 10.1016/j.clgc.2018.08.003. [Epub ahead of print]

PMID:
30217764
9.

Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma.

Zahoor H, Pavicic PG Jr, Przybycin C, Ko J, Stephens L, Radivoyevitch T, Jia X, Diaz-Montero CM, Finke J, Rayman PA, Gilligan TD, Grivas P, Ornstein M, Garcia JA, Rini BI.

Medicine (Baltimore). 2018 Sep;97(37):e12344. doi: 10.1097/MD.0000000000012344.

10.

Information Transparency in the Drug Approval Process.

Rini BI, Burstein HJ, George DJ.

JAMA Oncol. 2018 Nov 1;4(11):1621-1622. doi: 10.1001/jamaoncol.2018.4143. No abstract available.

PMID:
30193367
11.

Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma.

Barata PC, Mendiratta P, Kotecha R, Gopalakrishnan D, Juloori A, Chao ST, Koshkin V, Ornstein M, Gilligan TD, Wood LS, Rini BI, Angelov L, Garcia JA.

Clin Genitourin Cancer. 2018 Oct;16(5):413-419.e1. doi: 10.1016/j.clgc.2018.07.018. Epub 2018 Aug 17.

PMID:
30172552
12.

The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era.

Chen YW, Ornstein MC, Wood LS, Allman KD, Martin A, Beach J, Gilligan T, Garcia JA, Rini BI.

Urol Oncol. 2018 Oct;36(10):470.e19-470.e29. doi: 10.1016/j.urolonc.2018.06.013. Epub 2018 Aug 18.

PMID:
30131292
13.

Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.

Barata P, Emamekhoo H, Mendiratta P, Koshkin V, Tyler A, Ornstein M, Rini BI, Gilligan T, Kyriakopoulos C, Garcia JA.

Prostate. 2018 Sep;78(13):1035-1041. doi: 10.1002/pros.23663. Epub 2018 Jun 7.

PMID:
29882332
14.

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. Epub 2018 Jun 4. Erratum in: Nat Med. 2018 Oct 5;:.

PMID:
29867230
15.

Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.

Rini BI, Hutson TE, Figlin RA, Lechuga MJ, Valota O, Serfass L, Rosbrook B, Motzer RJ.

Clin Genitourin Cancer. 2018 Aug;16(4):298-304. doi: 10.1016/j.clgc.2018.04.005. Epub 2018 May 4.

PMID:
29853320
16.

The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma.

Barata PC, De Liano AG, Mendiratta P, Crolley V, Szabados B, Morrison L, Wood L, Allman K, Tyler A, Martin A, Gilligan T, Grivas P, Ornstein M, Garcia JA, Powles T, Rini BI.

Br J Cancer. 2018 Jul;119(2):160-163. doi: 10.1038/s41416-018-0104-z. Epub 2018 May 24.

PMID:
29795307
17.

Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib.

Rini BI, Escudier B, Martini JF, Magheli A, Svedman C, Lopatin M, Knezevic D, Goddard AD, Febbo PG, Li R, Lin X, Valota O, Staehler M, Motzer RJ, Ravaud A.

Clin Cancer Res. 2018 Sep 15;24(18):4407-4415. doi: 10.1158/1078-0432.CCR-18-0323. Epub 2018 May 17.

PMID:
29773662
18.

Current and emerging first-line systemic therapies in clear cell renal cell carcinoma.

Rini BI.

Clin Adv Hematol Oncol. 2018 Feb;16(2):115-117. No abstract available.

PMID:
29741511
19.

Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma.

Jonasch E, Slack RS, Geynisman DM, Hasanov E, Milowsky MI, Rathmell WK, Stovall S, Juarez D, Gilchrist TR, Pruitt L, Ornstein MC, Plimack ER, Tannir NM, Rini BI.

J Clin Oncol. 2018 Jun 1;36(16):1588-1593. doi: 10.1200/JCO.2017.77.1485. Epub 2018 Apr 11.

PMID:
29641297
20.

Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies.

Barata PC, Gopalakrishnan D, Koshkin VS, Mendiratta P, Karafa M, Allman K, Martin A, Beach J, Profusek P, Tyler A, Wood L, Ornstein M, Gilligan T, Rini BI, Garcia JA, Grivas P.

Target Oncol. 2018 Jun;13(3):353-361. doi: 10.1007/s11523-018-0561-6.

PMID:
29623487
21.

Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.

Ornstein MC, Diaz-Montero CM, Rayman P, Elson P, Haywood S, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Devonshire S, Dann P, Schach K, Stephenson A, Campbell S, Emamekhoo H, Ernstoff MS, Hoimes CJ, Gilligan TD, Rini BI, Garcia JA, Grivas P.

Urol Oncol. 2018 Sep;36(9):405-412. doi: 10.1016/j.urolonc.2018.02.018. Epub 2018 Mar 30. Review.

PMID:
29606341
22.

Extended therapy breaks from VEGFR TKI therapy in renal cell carcinoma: Sometimes less is more.

Zahoor H, Rini BI, Ornstein MC.

Oncotarget. 2017 Dec 6;9(18):14036-14037. doi: 10.18632/oncotarget.23005. eCollection 2018 Mar 6. No abstract available.

23.

Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function.

Koshkin VS, Barata PC, Rybicki LA, Zahoor H, Almassi N, Redden AM, Fergany AF, Kaouk J, Haber GP, Stephenson AJ, Ornstein MC, Gilligan T, Garcia JA, Rini BI, Grivas P.

Clin Genitourin Cancer. 2018 Aug;16(4):e879-e892. doi: 10.1016/j.clgc.2018.02.002. Epub 2018 Feb 22.

PMID:
29576445
24.

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators.

N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.

25.

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.

Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D, Robbins PB, Chism DD, Cho D, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, Fowst C, di Pietro A, Rini BI.

Lancet Oncol. 2018 Apr;19(4):451-460. doi: 10.1016/S1470-2045(18)30107-4. Epub 2018 Mar 9.

PMID:
29530667
26.

Goldilocks Dosing of TKIs: A Dose that Is Just Right Leads to Optimal Outcomes.

Rini BI.

Clin Cancer Res. 2018 Jul 1;24(13):2979-2980. doi: 10.1158/1078-0432.CCR-18-0291. Epub 2018 Mar 9.

PMID:
29523625
27.

A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma.

Liu X, Swen JJ, Diekstra MHM, Boven E, Castellano D, Gelderblom H, Mathijssen RHJ, Vermeulen SH, Oosterwijk E, Junker K, Roessler M, Alexiusdottir K, Sverrisdottir A, Radu MT, Ambert V, Eisen T, Warren A, Rodríguez-Antona C, García-Donas J, Böhringer S, Koudijs KKM, Kiemeney LALM, Rini BI, Guchelaar HJ.

Clin Cancer Res. 2018 May 15;24(10):2350-2356. doi: 10.1158/1078-0432.CCR-17-2815. Epub 2018 Feb 28.

PMID:
29490989
28.

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.

Koshkin VS, Barata PC, Zhang T, George DJ, Atkins MB, Kelly WJ, Vogelzang NJ, Pal SK, Hsu J, Appleman LJ, Ornstein MC, Gilligan T, Grivas P, Garcia JA, Rini BI.

J Immunother Cancer. 2018 Jan 29;6(1):9. doi: 10.1186/s40425-018-0319-9.

29.

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.

Courtney KD, Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas J, Zojwalla NJ, Lowe AM, Wang K, Wallace EM, Josey JA, Choueiri TK.

J Clin Oncol. 2018 Mar 20;36(9):867-874. doi: 10.1200/JCO.2017.74.2627. Epub 2017 Dec 19.

PMID:
29257710
30.

Organ Preservation for Recurrent Urethral Adenocarcinoma With Concurrent Chemotherapy and Radiation.

Mendiratta P, Rini BI, Tendulkar RD.

Urology. 2018 Mar;113:e1-e2. doi: 10.1016/j.urology.2017.11.033. Epub 2017 Dec 2.

PMID:
29203190
31.

HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism.

Du W, Zhang L, Brett-Morris A, Aguila B, Kerner J, Hoppel CL, Puchowicz M, Serra D, Herrero L, Rini BI, Campbell S, Welford SM.

Nat Commun. 2017 Nov 24;8(1):1769. doi: 10.1038/s41467-017-01965-8.

32.

Renal Functional Outcome of Partial Nephrectomy for Complex R.E.N.A.L. Score Tumors With or Without Neoadjuvant Sunitinib: A Multicenter Analysis.

McDonald ML, Lane BR, Jimenez J, Lee HJ, Yim K, Bindayi A, Hamilton ZA, Field CA, Bloch AS, Dey S, Noyes S, McKay R, Millard F, Rini BI, Campbell SC, Derweesh IH.

Clin Genitourin Cancer. 2018 Apr;16(2):e289-e295. doi: 10.1016/j.clgc.2017.09.007. Epub 2017 Sep 25.

PMID:
29113767
33.

Treatment of renal cell carcinoma: Current status and future directions.

Barata PC, Rini BI.

CA Cancer J Clin. 2017 Nov;67(6):507-524. doi: 10.3322/caac.21411. Epub 2017 Sep 29. Review.

34.

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Melichar B, Rini BI, Choueiri TK, Zemanova M, Wood LA, Reaume MN, Stenzl A, Chowdhury S, Lim HY, McDermott R, Michael A, Bao W, Carrasco-Alfonso MJ, Aimone P, Voi M, Doehn C, Russo P, Sternberg CN; PROTECT investigators.

J Clin Oncol. 2017 Dec 10;35(35):3916-3923. doi: 10.1200/JCO.2017.73.5324. Epub 2017 Sep 13.

35.

Emerging immunotherapy in advanced renal cell carcinoma.

Mendiratta P, Rini BI, Ornstein MC.

Urol Oncol. 2017 Dec;35(12):687-693. doi: 10.1016/j.urolonc.2017.08.011. Epub 2017 Sep 8. Review.

PMID:
28889919
36.

Imaging strategy and outcome following partial nephrectomy.

Mouracade P, Chavali JS, Kara O, Dagenais J, Maurice MJ, Nelson RJ, Rini BI, Kaouk JH.

Urol Oncol. 2017 Nov;35(11):660.e1-660.e8. doi: 10.1016/j.urolonc.2017.06.052. Epub 2017 Aug 31.

PMID:
28863862
37.

Perinephric and Sinus Fat Invasion in Stage pT3a Tumors Managed by Partial Nephrectomy.

Mouracade P, Dagenais J, Chavali JS, Kara O, Nelson RJ, Maurice MJ, Reese J, Rini BI, Kaouk JH.

Clin Genitourin Cancer. 2018 Oct;16(5):e1077-e1082. doi: 10.1016/j.clgc.2017.07.019. Epub 2017 Jul 26.

PMID:
28818550
38.

Neoadjuvant therapy for localized and locally advanced renal cell carcinoma.

Bindayi A, Hamilton ZA, McDonald ML, Yim K, Millard F, McKay RR, Campbell SC, Rini BI, Derweesh IH.

Urol Oncol. 2018 Jan;36(1):31-37. doi: 10.1016/j.urolonc.2017.07.015. Epub 2017 Aug 10. Review.

PMID:
28802883
39.

Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC).

Yip SM, Ruiz Morales JM, Donskov F, Fraccon A, Basso U, Rini BI, Lee JL, Bjarnason GA, Sim HW, Beuselinck B, Kanesvaran R, Brugarolas J, Koutsoukos K, Fu SYF, Yuasa T, Davis I, Alva A, Kollmannsberger C, Choueiri TK, Heng DYC.

Kidney Cancer. 2017 Jul 26;1(1):41-47. doi: 10.3233/KCA-160002.

40.

Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials.

Tannir NM, Figlin RA, Gore ME, Michaelson MD, Motzer RJ, Porta C, Rini BI, Hoang C, Lin X, Escudier B.

Clin Genitourin Cancer. 2017 Jun 20. pii: S1558-7673(17)30171-4. doi: 10.1016/j.clgc.2017.06.005. [Epub ahead of print]

PMID:
28711490
41.

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.

Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, Voss MH, Sharma P, Pal SK, Razak ARA, Kollmannsberger C, Heng DYC, Spratlin J, McHenry MB, Amin A.

J Clin Oncol. 2017 Dec 1;35(34):3851-3858. doi: 10.1200/JCO.2016.72.1985. Epub 2017 Jul 5.

PMID:
28678668
42.

Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma.

Apellániz-Ruiz M, Diekstra MH, Roldán JM, Boven E, Castellano D, Gelderblom H, Mathijssen RHJ, Swen JJ, Böhringer S, García-Donás J, Rini BI, Guchelaar HJ, Rodríguez-Antona C.

Pharmacogenet Genomics. 2017 Jun;27(6):227-231. doi: 10.1097/FPC.0000000000000280.

PMID:
28430711
43.

Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma.

Rini BI, Gruenwald V, Jonasch E, Fishman MN, Tomita Y, Michaelson MD, Tarazi J, Cisar L, Hariharan S, Bair AH, Rosbrook B, Hutson TE.

Target Oncol. 2017 Jun;12(3):333-340. doi: 10.1007/s11523-017-0487-4.

PMID:
28361451
44.

Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study.

Oya M, Tomita Y, Fukasawa S, Shinohara N, Habuchi T, Rini BI, Fujii Y, Kamei Y, Umeyama Y, Bair AH, Uemura H.

Cancer Sci. 2017 Jun;108(6):1231-1239. doi: 10.1111/cas.13232. Epub 2017 May 22.

45.

Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma.

De Velasco G, Xie W, Donskov F, Albiges L, Beuselinck B, Srinivas S, Agarwal N, Lee JL, Brugarolas J, Wood LA, Rha SY, Kollmannsberger C, North S, Kanesvaran R, Rini BI, Broom R, Yamamoto H, Kaymakcalan MD, Heng DYC, Choueiri TK.

Clin Genitourin Cancer. 2017 Jun;15(3):403-410.e2. doi: 10.1016/j.clgc.2017.01.005. Epub 2017 Jan 12.

PMID:
28254206
46.

Specific immunotherapy in renal cancer: a systematic review.

Hirbod-Mobarakeh A, Gordan HA, Zahiri Z, Mirshahvalad M, Hosseinverdi S, Rini BI, Rezaei N.

Ther Adv Urol. 2017 Feb;9(2):45-58. doi: 10.1177/1756287216681246. Epub 2016 Dec 19. Review.

47.

A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma.

Ornstein MC, Wood LS, Elson P, Allman KD, Beach J, Martin A, Zanick BR, Grivas P, Gilligan T, Garcia JA, Rini BI.

J Clin Oncol. 2017 Jun 1;35(16):1764-1769. doi: 10.1200/JCO.2016.71.1184. Epub 2017 Jan 23.

PMID:
28113029
48.

The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma.

Voss MH, Bhatt RS, Plimack ER, Rini BI, Alter RS, Beck JT, Wilson D, Zhang X, Mutyaba M, Glasser C, Attie KM, Sherman ML, Pandya SS, Atkins MB.

Clin Cancer Res. 2017 Jul 15;23(14):3557-3565. doi: 10.1158/1078-0432.CCR-16-2395. Epub 2016 Dec 28.

49.

Future Challenges for Drug Development in Renal Cell Carcinoma.

Rini BI, Vogelzang NJ.

J Clin Oncol. 2017 Feb 20;35(6):577-579. doi: 10.1200/JCO.2016.71.0673. Epub 2016 Dec 19. No abstract available.

PMID:
27992269
50.

On-treatment biomarkers in metastatic renal cell carcinoma: towards individualization of prognosis?

Donskov F, Heng DY, Rini BI.

Expert Rev Anticancer Ther. 2017 Feb;17(2):97-99. doi: 10.1080/14737140.2017.1269605. Epub 2016 Dec 20. No abstract available.

PMID:
27927054

Supplemental Content

Loading ...
Support Center